The efficacy and safety of prophylaxis with wilate, a plasma-derived von Willebrand factor/factor VIII concentrate, was demonstrated in patients with von Willebrand disease of all types in the WIL-31 study. Here, VWF is linked to platelet-type von Willebrand disease.